update

endpoint named preferred provider for Ferring Pharmaceuticals

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/shironosov)
(Image: iStock/shironosov)
Ferring Pharmaceuticals has selected endpoint as its sole leading interactive response technology (IRT) provider.

The preferred partnership extends a previously established relationship, which began in early 2015.

In a press statement, Chuck Harris, endpoint’s CEO described the preferred partnership as “a prime example of endpoint’s expansion across the global clinical trials industry.​”

"As a company who is exclusively focused on IRT, we are in a unique position to dedicate 100% of our resources and efforts to advancing our IRT solutions, thereby advancing the industry itself​," Harris told us.

According to the company, endpoint continues to grow in Europe through its full-service IRT solution, PULSE, and its enterprise supply management hub, DRIVE.

"Over the last year, we have made substantial progress in expanding our operations footprint across the globe, enabling endpoint to be better positioned geographically within several markets outside of the US, and by pushing the boundaries of ‘what is IRT’ through the expansion of its offerings​," Ryan Keane, Executive Director, Business Development, told Outsourcing-Pharma.com.

The clinical supply management tool, DRIVE, was introduced last year​ at DIA 2016 in June. The offering enables IRT functionality for non-IRT and investigator-sponsored trials.

The tool allows users to manage all elements of non-IRT and endpoint IRT studies electronically within a single system, with the ability to see supply at depots through a single view. 

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers